ArticleArthritis care & research2014
Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus.
Article in Arthritis care & research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Coronary artery calcification progression and renal involvement in patients with systemic lupus erythematosus: a longitudinal cohort study.Rheumatology international · 2025Article
- The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2024Article
- Cardiovascular issues in rheumatic diseases.Clinical rheumatology · 2023Review
- Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus.International journal of molecular sciences · 2022Review
- Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease.Cureus · 2021Review
- A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.ACR open rheumatology · 2021Article
- Nocturnal blood pressure dipping as a marker of endothelial function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus.Arthritis research & therapy · 2020Article
- Utility of Coronary Calcium Scoring (CCS) in Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis - A Systematic Review.ACR open rheumatology · 2020Article
- Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients.Lupus science & medicine · 2020Article
- Article
- Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus.Rheumatology international · 2019Article
- Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus.PloS one · 2018Article
- Association between ischemic heart disease and systemic lupus erythematosus-a large case-control study.Immunologic research · 2017Article
- Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.Frontiers in medicine · 2017Review
- Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus.Arthritis care & research · 2017Article
- Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity and damage indices.Zeitschrift fur Rheumatologie · 2015Article
- Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study.Arthritis research & therapy · 2015Article
- Pathogenesis and treatment of atherosclerosis in lupus.Rheumatic diseases clinics of North America · 2014Review
- Aortic Atherosclerosis in Systemic Lupus Erythematosus.Rheumatology (Sunnyvale, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo investigate risk factors in subclinical atherosclerosis progression as measured by coronary artery calcium (CAC) and aorta calcium (AC) in women with systemic lupus erythematosus (SLE; cases) and in comparison with a control population.
methodsA cohort of 149 cases and 124 controls participated in the Study of Lupus Vascular and Bone Long-Term Endpoints. Demographic information, cardiovascular and SLE risk factors, and laboratory assessments were collected at an initial visit. CAC and AC were measured by electron beam computed tomography (CT) or multidetector CT at an initial visit and at a followup visit. Logistic regression models were used to identify predictors of progression in CAC and AC; multivariate models were adjusted for age, hypertension, and total cholesterol to high-density lipoprotein ratio.
resultsHigher modified Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score (odds ratio [OR] 2.15, 95% confidence interval [95% CI] 1.33-3.57), use of a corticosteroid (OR 2.93, 95% CI 1.14-7.86), and use of aspirin (OR 4.23, 95% CI 1.53-11.74) were associated with CAC progression in multivariate models. Presence of SLE (OR 2.64, 95% CI 1.26-5.72), lower C3 (OR 0.54, 95% CI 0.33-0.87), lower C4 (OR 0.49, 95% CI 0.27-0.86), use of a corticosteroid (OR 2.73, 95% CI 1.03-7.64), higher corticosteroid dose (OR 1.77, 95% CI 1.12-3.00), higher lipoprotein(a) (OR 1.80, 95% CI 1.11-2.98), and higher homocysteine (OR 2.06, 95% CI 1.06-4.29) were associated with AC progression in multivariate models.
conclusionHigher disease damage at the first study visit, as measured by the modified SDI, may predict increased risk in CAC progression, whereas higher disease activity at the first study visit, as measured by hypocomplementemia and use of corticosteroids, may predict increased risk in AC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.